A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome).

Trial Profile

A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs AGT 181 (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Adverse reactions; Proof of concept
  • Sponsors ArmaGen Technologies
  • Most Recent Events

    • 30 Nov 2017 According to an ArmaGen Technologies media release, this study has fully enrolled and company expects to present final results at the 14th Annual WORLDSymposium in Feb 2018.
    • 16 Feb 2017 Preliminary results (n=5) from the phase II portion of this trial presented at the 13th annual WORLDSymposium 2017, according to an ArmaGen Technologies media release.
    • 16 Feb 2017 Preliminary results (n=5) from the phase II portion of this trial published in an ArmaGen Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top